Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Schrum Private Wealth Management LLC

Schrum Private Wealth Management LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 100.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,804 shares of the company’s stock after purchasing an additional 2,402 shares during the period. Schrum Private Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $572,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. 1620 Investment Advisors Inc. acquired a new position in Novo Nordisk A/S in the 2nd quarter valued at about $25,000. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S in the second quarter valued at approximately $25,000. Orion Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth $26,000. Gilliland Jeter Wealth Management LLC grew its position in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares during the last quarter. Finally, Halpern Financial Inc. increased its stake in Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after buying an additional 113 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on NVO shares. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded up $0.29 during trading on Wednesday, hitting $107.35. 956,590 shares of the stock were exchanged, compared to its average volume of 4,430,909. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The company has a market cap of $481.74 billion, a PE ratio of 34.68, a P/E/G ratio of 1.32 and a beta of 0.42. The company has a fifty day moving average price of $120.23 and a two-hundred day moving average price of $130.08. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.